BKGD Knockout HeLa Polyclonal Cells are a CRISPR/Cas9-edited polyclonal population with targeted disruption of the BKGD gene in the HeLa cell line. This product provides a loss-of-function model for investigating BKGD’s roles in branched-chain amino acid metabolism and cellular energy homeostasis. As a polyclonal pool, the cells reflect heterogeneous editing events, enabling study of gene function without clonal artifacts. The knockout model serves as a versatile platform for metabolic research, cancer biology, and disease modeling.
The HeLa cell line is an immortalized human epithelial line from a cervical adenocarcinoma biopsy (Henrietta Lacks). HeLa cells are HPV18-positive, and the viral E6 oncoprotein inactivates p53, contributing to their transformed phenotype and robust proliferation. This background makes HeLa valuable for studying cancer metabolism, signaling, and therapeutic responses. The model provides a stable platform for generating gene knockouts and analyzing metabolic adaptations in a cancer context.
The BKGD gene encodes a subunit of the branched-chain ??-keto acid dehydrogenase (BCKD) complex, which decarboxylates ??-keto acids from leucine, isoleucine, and valine. The complex includes BKGDHA, BKGDHB, DBT, and DLD subunits. Its activity is regulated by the kinase BCKDK and phosphatase PPM1K, responding to dietary BCAA levels and insulin. BKGD disruption impairs BCAA catabolism, reducing acetyl-CoA and succinyl-CoA production that feed the TCA cycle, thereby affecting NADH generation and energy metabolism.
In HeLa cancer cells, BKGD loss perturbs the intersection of BCAA degradation and central carbon metabolism. HeLa cells rely on glutamine and glucose, but BCAA oxidation contributes to TCA cycle anaplerosis and lipogenesis. BKGD knockout may redirect metabolic fluxes, sensitizing cells to nutrient deprivation or altering redox balance. Given the links between BCAA metabolism and cancer, this model enables dissection of how BCKD deficiency impacts tumor viability, mitochondrial respiration, and metabolic vulnerability, with implications for maple syrup urine disease (MSUD) and metabolic syndromes.
Researchers can employ these cells in Western blotting and RT-qPCR to confirm BKGD disruption, metabolic flux analysis with labeled BCAAs, and LC-MS profiling of TCA cycle intermediates. The polyclonal population is well suited for studying metabolic stress responses, such as proliferation under amino acid deprivation and oxygen consumption rate assays by Seahorse, to delineate mitochondrial function. This knockout tool further supports mechanistic studies of BCKD complex regulation, small-molecule screening, and investigation of neurological metabolic disorders. For technical inquiries, please contact Ascent Research.
